Delve into Eli Lilly’s biopharma strategy as it advances its pipeline, wins regulatory milestones, and forges strategic deals ...
Medicare Part D beneficiaries experienced a large increase in out-of-pocket spending for GLP-1s in 2025, according to ...
Millions of Americans who could benefit from GLP-1 weight-loss drugs are caught in the middle of a battle between drug ...
From a federal judge tossing a Medicare Advantage audit rule to Florida hospitals challenging a proposed transplant rule, here are 10 ...
Bank of America Global Healthcare Conference 2025 September 23, 2025 8:20 AM EDTCompany ParticipantsMichael Farrell - CEO ...
Patients taking an experimental oral GLP-1 drug lost significant weight and improved heart and metabolic risk factors in a large, international phase ...
Curious about the latest updates in the Obstructive Sleep Apnea Pipeline? Click here to explore the therapies and trials ...
A variety of laboratory tests are available to determine whether a patient has good sleep health, but a simple way to ...
AZoLifeSciences on MSN
Ozempic 2025: Evolving Indications, Competition, Regulation, and Real-World Realities
Ozempic, containing semaglutide, aids weight loss and diabetes management while offering cardiovascular and kidney protection ...
The Eli Lilly and Company-Bond has a maturity date of 10/15/2035 and offers a coupon of 4.9000%. The payment of the coupon will take place 2,0 times per biannual on the 15.04.. At the current price of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback